8 completed, 1 terminated. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Terminated 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Adult Nodular Sclerosis Hodgkin Lymphoma: new trials by email Literature Review of Adult Nodular Sclerosis Hodgkin Lymphoma trials Research Report on Adult Nodular Sclerosis Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 | Completed | Wake Forest University Health Sciences | 16 | 2014-09-01 | 2024-02-13 |
| Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma gemcitabine hydrochloride, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Beth Christian | 26 | 2012-02-09 | 2021-11-19 |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma brentuximab vedotin, doxorubicin hydrochloride, vinblastine - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 2 | Completed | Northwestern University | 49 | 2011-11-01 | 2026-05-22 |
| A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma panobinostat, lenalidomide - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 24 | 2011-10-13 | 2017-11-14 |
| Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy ifosfamide, bortezomib, vinorelbine tartrate - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2007-01-01 | 2021-03-24 |
| SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma monoclonal antibody SGN-30, placebo, vinorelbine tartrate - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2006-04-01 | 2015-02-23 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma alvocidib - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 46 | 2005-12-01 | 2016-08-08 |
| Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma vorinostat, laboratory biomarker analysis - Adult Favorable Prognosis Hodgkin Lymphoma, Adult Lymphocyte Depletion Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2005-09-01 | 2014-05-23 |
| Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma 17-N-allylamino-17-demethoxygeldanamycin/bortezomib - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2004-03-01 | 2015-12-04 |
Hodgkin Disease (9) · Immunoblastic Lymphadenopathy (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell, Cutaneous (2) · Mycosis Fungoides (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Sezary Syndrome (2) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoma (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Lymphadenopathy (2)
Bendamustine Hydrochloride (2) · Bortezomib (2) · Brentuximab Vedotin (2) · Gemcitabine (2) · Vinorelbine (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Amplified Fragment Length Polymorphism Analysis (1) · Dacarbazine (1) · Doxorubicin (1) · Filgrastim (1) · Fluorodeoxyglucose F18 (1) · Granulocyte Colony-Stimulating Factor (1) · Histone Deacetylase Inhibitors (1) · Hydroxamic Acids (1) · Ifosfamide (1)
National Cancer Institute (NCI) (5) · Beth Christian (1) · Northwestern University (1) · Ohio State University Comprehensive Cancer Center (1) · Wake Forest University Health Sciences (1)
United States (9)
Beth Christian, MD (1) · Jeffrey Jones (1) · Kristie Blum (1) · Kristie Blum, MD (1) · Leo Gordon, MD (1) · Mark Kirschbaum (1) · Nancy Bartlett (1) · Rakhee Vaidya (1) · Terzah Horton (1)
PMID 24241210, PMID 25833390, PMID 28622959, PMID 30179569
U10CA031946 (2), N01CM00070 (1), P30CA012197 (1), P30CA014236 (1), P30CA016058 (1), U01CA076576 (1), U10CA032102 (1), U10CA098543 (1)